Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind double-dummy study of MT1013 versus cinacalcet in maintenance dialysis patients with secondary hyperparathyroidism
CTR20253125Phase 3Active
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of MT1013 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Sep 2025; status: active.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20253125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253125.